February 14, 2025, Mumbai – Kilitch Drugs Limited, BSE and NSE listed, a leading pharmaceutical company specializing in the manufacturing and distribution of high-quality Parenteral, Injectables, Oral Solids, and Effervescent, announced its unaudited financial results for the quarter and nine months ended 31st December 2024.
The company’s reported a 222% per cent year-on-year(Y-o-Y) remarkable rise in consolidated profit after tax (PAT) for the Q3 FY25 to Rs. 5.61 crore from Rs. 1.74 crore for the corresponding period previous year.
The company recorded its quarterly consolidated revenue from operations at Rs. 56.17 crore in Q3FY25, experiencing 77 per cent of Y-o-Y excellence growth from Rs. 31.79 crore in Q3 FY24. The growth is achieved by continuous efforts to meet steady demand across globe and will continue further.
Consecutively, the company’s standalone PAT rose by 25% per cent, and revenue grew by 56 per cent to Rs 6.88 crore and Rs 46.51 crore recorded in Q3 FY25, respectively.
For the nine months ending December 2024 (9MFY25), Kilitch reported an over 42 percent YoY rise in net profit to ₹19.78 crore, compared to ₹13.93 crore in 9MFY24. Revenue from operation for the period increased by 35 percent to ₹125.28 crore from ₹92.46 crore in the previous year.
Commenting on the Q3FY25 performance, Mr. Mukund Mehta, Chairman & Managing Director of Kilitch Drugs said, “We witnessed significant growth in our performance this quarter; revenue from operations grew by 35% on standalone basis. We remain focused on driving sustainable growth and delivering strong returns for our stakeholders.”
